O Shaughnessy Asset Management LLC Purchases 207,577 Shares of Haleon plc (NYSE:HLN)

O Shaughnessy Asset Management LLC lifted its holdings in Haleon plc (NYSE:HLN) by 141.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 354,436 shares of the company’s stock after purchasing an additional 207,577 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Haleon were worth $3,381,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Wellington Management Group LLP increased its holdings in shares of Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after buying an additional 3,046,841 shares during the last quarter. Douglas Lane & Associates LLC grew its position in Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after acquiring an additional 161,865 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Haleon by 18.3% during the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company’s stock worth $57,382,000 after acquiring an additional 930,701 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Haleon during the fourth quarter valued at approximately $42,193,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Haleon in the 4th quarter valued at approximately $39,628,000. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Finally, Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.95.

Haleon Trading Up 2.8 %

NYSE HLN opened at $10.45 on Friday. The stock has a market cap of $47.29 billion, a PE ratio of 30.72, a PEG ratio of 2.82 and a beta of 0.25. Haleon plc has a 12 month low of $7.99 and a 12 month high of $10.80. The company’s 50-day moving average price is $10.02 and its 200-day moving average price is $9.87. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Equities research analysts forecast that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s payout ratio is 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.